Schott, a global leader in pharmaceutical glass manufacturing, is investing a total of 70 million Euros (approximately Indian Rs 600 crore) in the expansion of its Indian tubing site in Jambusar, Gujarat, following several million investments in the last few years.
“Against the backdrop of the growth trend in the Indian pharmaceutical business and the pandemic, we want to commit to secure the supply of pharma glass,” explains Patrick Markschläger, executive vice president of Schott’s Business Unit Tubing.
“The increase of over 30% in the facility’s overall Indian production capacity is at the same time a commitment to supporting the government’s vision of India becoming a global pharmaceutical hub,” adds Pawan Shukla, managing director Schott Glass India, during the groundbreaking event at the site.
The additional tank is scheduled to operate at the beginning of 2023, with the second one following a year later. The expansion in Jambusar will create new jobs for around 225 employees and is part of Schott’s more than US$ 1 billion strategic investment program through 2025, leveraging the global pharma tubing and packaging business.
Schott fiolax glass usage in vaccine packaging
Schott has been a frontrunner in the fight against Covid-19 and provided pharmaceutical glass for primary packaging to fill billions of Covid-19 vaccines worldwide. In India, almost all approved vaccines are packed in Fiolax glass made by Schott. With additional melting tanks and production lines, Schott intends to ensure that this Asian manufacturing hub can adequately supply high-quality pharma glass for the Indian pharma industry and neighboring countries.
The increase of melting capacities in India, supplemented by a batch house, a driveway, and a canteen for the employees, is part of Schott’s commitment to invest over Euro 100 million (Indian Rupees 840 crore) in its Indian tubing facilities and triple production capacity to produce Fiolax glass tubing for domestic and export demands.
